Posts

Agios Licenses Oscotec Blood Disorder Drug Cevidoplenib in $165M Deal Despite Phase 2 Setback

on

Novartis antibody ianalumab helps prolong control of rare blood disorder ITP

on

CHMP Rejects Sanofi’s Rezurock Over Clinical Data Issues, Recommends Approval of BTK Inhibitor Wayrilz

on

Sanofi’s Wayrilz Receives FDA Approval as First BTK Inhibitor for Immune Thrombocytopenia

on

Novartis antibody ianalumab clinches another Phase 3 win in rare blood disease (ITP)

on